180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, today announced that a team led by researchers at University of Oxford were awarded a grant from the National Institute for Health and Care Research (“NIHR”) in the U.K. to conduct a feasibility trial. The trial will investigate whether anti-tumor necrosis factor (“TNF”) therapy, administered at the time of surgery, can reduce or prevent post operative delirium/cognitive deficit (“post-operative delirium”). “This is a major achievement by the team,” said Dr. Jim Woody, CEO of 180 Life Sciences. “These grants are awarded following a robust peer-review process and are extremely competitive. It means that the team will be able to access many services essential for the conduct of the trial funded by the NIHR, and 180 Life Sciences is delighted to be able to make a significant contribution to further the trial. This dual funding model and collaboration between academia and industry leverages the expertise of both to develop new therapeutic strategies for what we believe is a major unmet medical need, in the most effective way to benefit patients in the shortest possible timescale.”

To view the full press release, visit https://ibn.fm/1EozC

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company. The company is driving groundbreaking studies into clinical programs, which are seeking to develop treatments for major unmet clinical needs. The company’s primary platform is a novel program to treat inflammatory disorders using anti-TNF (tumor necrosis factor). For more information, visit the company’s website at www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.